PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Procarta announces €1.5 million investment for new class of antibiotics to combat antimicrobial resistance

Stevenage, UK, 5th March 2019 / Sciad Newswire / Procarta Biosystems, a privately held UK-based biotech company, today announced €1.5m of new funding from the Novo Holdings REPAIR Impact Fund to support development of novel therapies to combat antimicrobial resistance (AMR). The new funding will be used to develop a pipeline of an entirely new class of antibiotic precision medicines from Procarta’s proprietary oligonucleotide-based antimicrobial platform.
Procarta’s lead asset, PRO-202, is in preclinical development to treat complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). The ESKAPE pathogens (Enterococcus faeciumStaphylococcus aureusKlebsiella pneumoniaeAcinetobacter baumanniiPseudomonas aeruginosa, and Enterobacter species) are responsible for a significant proportion of cUTIs and cIAIs throughout the world. Moreover, ESKAPE pathogens represent the greatest risk of antibiotic resistance of all clinical infections. Of particular note are the carbapenem-resistant Enterobacteriaceae (CRE), a sub-group of Gram-negative bacteria, e.g. Escherichia coli and Klebsiella species, which are resistant to the carbapenem class of antimicrobials. CRE are often considered as the worst new “superbugs” as these bacteria can kill up to half of the patients who develop bloodstream infections from these pathogens. Worryingly, carbapenem resistance is growing exponentially – resistant Klebsiella rose from 0.6% to 5.4% between 2004 and 2008 in the US, and in Thailand 70% of Pseudomonas infections are carbapenem resistant.
Dr Andrew Lightfoot, PhD, MBA, Chief Executive Officer of Procarta, commented “The REPAIR investment comes in alongside investment from Procarta’s founding investor the UK Innovation & Science Seed Fund (UKI2S), as well as Wren Capital, Meltwind and Development Bank Wales. The money will be used to progress our lead asset, PRO-202 and to develop our proprietary drug discovery platform to build a pipeline of antimicrobial agents to cover the ESKAPE pathogens.
“If the industry keeps prosecuting the same antibiotic drug targets, we will get the same answers, i.e. growing antimicrobial resistance. At Procarta, we believe it is time to explore novel modalities and targets to precipitate a paradigm shift in antimicrobial research. We are delighted that the REPAIR Impact Fund shares our vision and recognises the potential of Procarta’s novel approach.”
Aleks Engel, PhD, Director of the REPAIR Impact Fund, commented “Procarta’s transcription factor decoy platform is precisely the type of novel modality that we hoped we would find when we launched the fund a year ago. We see the technology as having immense potential as the basis for new approaches to new therapeutics development in infectious disease and beyond.”
Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40